Larry P. Feigen

2.1k total citations
59 papers, 1.7k citations indexed

About

Larry P. Feigen is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Larry P. Feigen has authored 59 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 16 papers in Cardiology and Cardiovascular Medicine and 16 papers in Physiology. Recurrent topics in Larry P. Feigen's work include Platelet Disorders and Treatments (18 papers), Nitric Oxide and Endothelin Effects (14 papers) and Antiplatelet Therapy and Cardiovascular Diseases (12 papers). Larry P. Feigen is often cited by papers focused on Platelet Disorders and Treatments (18 papers), Nitric Oxide and Endothelin Effects (14 papers) and Antiplatelet Therapy and Cardiovascular Diseases (12 papers). Larry P. Feigen collaborates with scholars based in United States, United Kingdom and Czechia. Larry P. Feigen's co-authors include Fletcher B. Taylor, TC Wun, Abla A. Creasey, Alvin Chang, L. B. Hinshaw, B. M. Chapnick, Nancy S. Nicholson, Philip J. Kadowitz, Susan G. Panzer‐Knodle and Aldo A. Luisada and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Investigation.

In The Last Decade

Larry P. Feigen

57 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Larry P. Feigen United States 23 599 436 332 257 241 59 1.7k
M.R. BARNARD United States 21 837 1.4× 837 1.9× 312 0.9× 122 0.5× 320 1.3× 30 2.2k
MH Kroll United States 10 1.1k 1.8× 558 1.3× 450 1.4× 101 0.4× 361 1.5× 15 1.9k
A. J. Hellem Norway 15 727 1.2× 528 1.2× 369 1.1× 108 0.4× 237 1.0× 26 1.7k
Emanuela Falcinelli Italy 24 757 1.3× 642 1.5× 188 0.6× 98 0.4× 266 1.1× 71 1.9k
Giuseppe Guglielmini Italy 22 376 0.6× 454 1.0× 101 0.3× 78 0.3× 175 0.7× 50 1.5k
Marc Verstraete Belgium 30 651 1.1× 1.1k 2.4× 615 1.9× 133 0.5× 828 3.4× 133 2.7k
Yasunori Abe Japan 19 430 0.7× 308 0.7× 206 0.6× 40 0.2× 316 1.3× 50 1.7k
Koichi Kawano Japan 17 268 0.4× 283 0.6× 155 0.5× 102 0.4× 365 1.5× 30 1.3k
Guadalupe Ortiz-Muñoz Spain 20 364 0.6× 130 0.3× 382 1.2× 63 0.2× 294 1.2× 23 2.1k
A. Auteri Italy 23 153 0.3× 476 1.1× 191 0.6× 118 0.5× 516 2.1× 96 1.7k

Countries citing papers authored by Larry P. Feigen

Since Specialization
Citations

This map shows the geographic impact of Larry P. Feigen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry P. Feigen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry P. Feigen more than expected).

Fields of papers citing papers by Larry P. Feigen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry P. Feigen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry P. Feigen. The network helps show where Larry P. Feigen may publish in the future.

Co-authorship network of co-authors of Larry P. Feigen

This figure shows the co-authorship network connecting the top 25 collaborators of Larry P. Feigen. A scholar is included among the top collaborators of Larry P. Feigen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry P. Feigen. Larry P. Feigen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicholson, Nancy S., Susan G. Panzer‐Knodle, James A. Szalony, et al.. (1998). Assessment of platelet function assays. American Heart Journal. 135(5). S170–S178. 127 indexed citations
2.
Badimón, Juan J., Barbara J Meyer, Larry P. Feigen, et al.. (1997). Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. European Journal of Clinical Investigation. 27(7). 568–574. 8 indexed citations
3.
Loftus, Joseph C., Carol Halloran, Mark H. Ginsberg, et al.. (1996). The Amino-terminal One-third of αIIb Defines the Ligand Recognition Specificity of Integrin αIIbβ3. Journal of Biological Chemistry. 271(4). 2033–2039. 61 indexed citations
4.
5.
Zablocki, Jeffery A., Foe S. Tjoeng, Philippe R. Bovy, et al.. (1995). A novel series of orally active antiplatelet agents. Bioorganic & Medicinal Chemistry. 3(5). 539–551. 30 indexed citations
6.
Panzer‐Knodle, Susan G., et al.. (1995). Characterization of Binding of an RGD Mimetic, [3H]-SC-52012, to Platelet GPIIb/IIIa. Platelets. 6(5). 288–295. 1 indexed citations
7.
Wu, Xiaobo, Miep Helfrich, M. A. Horton, Larry P. Feigen, & J B Lefkowith. (1994). Fibrinogen mediates platelet-polymorphonuclear leukocyte cooperation during immune-complex glomerulonephritis in rats.. Journal of Clinical Investigation. 94(3). 928–936. 42 indexed citations
8.
Nicholson, Nancy S., Susan G. Panzer‐Knodle, F. S. TJOENG, et al.. (1994). SC-49992-A potent and specific inhibitor of platelet aggregation. Thrombosis Research. 74(5). 523–535. 11 indexed citations
9.
Bovy, Philippe R., F. S. TJOENG, Thomas E. Rogers, et al.. (1994). Design of orally active, non-peptide fibrinogen receptor antagonists. An evolutionary process from the RGD sequence to novel anti-platelet aggregation agents. Bioorganic & Medicinal Chemistry. 2(9). 881–895. 10 indexed citations
10.
Creasey, Abla A., Alvin Chang, Larry P. Feigen, et al.. (1993). Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.. Journal of Clinical Investigation. 91(6). 2850–2860. 446 indexed citations
11.
Rote, William E., S.W. Werns, James H. Davis, et al.. (1993). Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Cardiovascular Research. 27(3). 500–507. 24 indexed citations
12.
Panzer‐Knodle, Susan G., et al.. (1993). Species variation in the effect of glycoprotein IIb/IIIa antagonists on inhibition of platelet aggregation. Journal of Pharmacological and Toxicological Methods. 30(1). 47–53. 10 indexed citations
13.
14.
Panzer‐Knodle, Susan G., et al.. (1991). Aminopeptidase resistant Arg‐Gly‐Asp analogs are stable in plasma and inhibit platelet aggregation. International journal of peptide & protein research. 38(2). 124–130. 12 indexed citations
15.
Pretus, Henry A., Louis J. Ignarro, Harry E. Ensley, & Larry P. Feigen. (1985). Inhibition of soybean lipoxygenase by SKF 525-A and metyrapone. Prostaglandins. 30(4). 591–598. 15 indexed citations
16.
Knight, David S., et al.. (1981). Intramedial Renal Arterial Nerves. Journal of Vascular Research. 18(4-5). 187–195. 2 indexed citations
17.
Feigen, Larry P., et al.. (1980). Peripheral vasodilator effects of prostaglandins: comparison of 6-keto-prostaglandin E1 with prostacyclin and escape from prostaglandin E2 in the mesenteric vascular bed.. Journal of Pharmacology and Experimental Therapeutics. 214(3). 528–534. 15 indexed citations
18.
Chapnick, B. M., et al.. (1978). Pulmonary and systemic vasodilator effects of prostacyclin. Federation Proceedings. 37(3). 3 indexed citations
19.
Luisada, Aldo A., Akira Sakai, & Larry P. Feigen. (1970). Comparative Electrocardiography and e Phonocardiography in Six Species of Animals. American Journal of Veterinary Research. 31(9). 1695–1702. 1 indexed citations
20.
Hansen, W., Larry P. Feigen, & S. Fine. (1967). A Worst-Case Analysis of Continuous Wave He–Ne Laser Hazards to the Eye. Applied Optics. 6(11). 1973–1973. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M.R. BARNARD Breakdown of academic impact, for papers by MH Kroll Breakdown of academic impact, for papers by A. J. Hellem Breakdown of academic impact, for papers by Emanuela Falcinelli Breakdown of academic impact, for papers by Giuseppe Guglielmini Breakdown of academic impact, for papers by Marc Verstraete Breakdown of academic impact, for papers by Yasunori Abe Breakdown of academic impact, for papers by Koichi Kawano Breakdown of academic impact, for papers by Guadalupe Ortiz-Muñoz Breakdown of academic impact, for papers by A. Auteri
Rankless by CCL
2026